FAQ: Branded Legacy's Air-Driven Intranasal Drug Delivery Platform Development
Summary
Branded Legacy, Inc. has begun engineering a unitary device mold for its proprietary air-driven intranasal drug delivery platform, advancing scalable production of single-use devices for rapid therapeutic delivery including inhaled naloxone. This development strengthens the company's capacity to address the opioid crisis through affordable, high-quality pharmaceutical solutions.
What is the main announcement from Branded Legacy, Inc.?
Branded Legacy announced that its subsidiary, BioLegacy Evaluative Group Inc., has begun engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform, advancing scalable production of single-use devices for rapid therapeutic delivery.
Why is this development significant?
This milestone strengthens Branded Legacy’s capacity to address the opioid crisis through affordable, high-quality pharmaceutical solutions, particularly through its flagship inhaled naloxone program for addiction treatment and harm reduction.
How does the air-driven intranasal drug delivery platform work?
The platform uses air-driven technology for intranasal drug delivery, enabling rapid and reliable therapeutic delivery through single-use devices that are now advancing toward scalable production.
Who is involved in this development?
Branded Legacy, Inc. (OTC: BLEG) is leading this initiative through its subsidiary BioLegacy Evaluative Group Inc., with strategic collaborations involving leading institutions like McMaster University and Stanford University.
When was the provisional patent filed for this technology?
The company filed a provisional patent in September 2025, establishing intellectual property protection for their proprietary air-driven intranasal drug delivery platform.
Where is Branded Legacy’s manufacturing facility located?
Branded Legacy operates a state-of-the-art GMP-compliant manufacturing facility in Vancouver, which provides advanced production capabilities for their pharmaceutical solutions.
What is the flagship application of this drug delivery platform?
The flagship application is inhaled naloxone, which represents a key component of the company’s strategy to address the opioid crisis through innovative addiction treatment and harm reduction solutions.
How does this development impact scalable production?
The engineering of the unitary device mold enables scalable production of single-use devices, allowing for mass manufacturing of the air-driven intranasal drug delivery platform to meet market demand.
Where can I find more information about Branded Legacy?
For more information, visit the company’s website at https://BrandedLegacy.com or view the full press release at https://ibn.fm/Lgrhz.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 265910